Domiziana Masci

Dr. Domiziana Masci

Catholic University of the Sacred Heart, Rome, Lazio, Italy
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GRGiuseppe La Regina
Giuseppe La Regina
RBRuoli Bai
Ruoli Bai
ACAntonio Coluccia
Antonio Coluccia
VNValentina Naccarato
Valentina Naccarato
VFValeria Famiglini
Valeria Famiglini
RSRomano Silvestri
Romano Silvestri

1 January 2017 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
SPSveva Pelliccia
Sveva Pelliccia
YWYu-Hsuan Wu
Yu-Hsuan Wu
ACAntonio Coluccia
Antonio Coluccia
GRGiuseppe La Regina
Giuseppe La Regina
CTChin-Kai Tseng
Chin-Kai Tseng
RSRomano Silvestri
Romano Silvestri
Dengue virus (DENV) is the leading mosquito-transmitted viral infection in the world. With more than 390 million new infections annually, and up to 1 million clinical cases with severe disease manifestations, there continues to be a need to develop new antiviral agents against dengue infection. In addition, there is no approved anti-DENV agents for treating DENV-infected patients. In the present study, we identified new compounds with anti-DENV replication activity by targeting viral replication enzymes – NS5, RNA-dependent RNA polymerase (RdRp) and NS3 protease, using cell-based reporter assay. Subsequently, we performed an enzyme-based assay to clarify the action of these compounds against DENV RdRp or NS3 protease activity. Moreover, these compounds exhibited anti-DENV activity in vivo in the ICR-suckling DENV-infected mouse model. Combination drug treatment exhibited a synergistic inhibition of DENV replication. These results describe novel prototypical small anti-DENV molecules for further development through compound modification and provide potential antivirals for treating DENV infection and DENV-related diseases.

1 September 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Domiziana MasciDomiziana Masci
Domiziana Masci
CHCharlotte Hind
Charlotte Hind
MIMohammad K. Islam
Mohammad K. Islam
ATAnita Toscani
Anita Toscani
MCMelanie Clifford
Melanie Clifford
Daniele CastagnoloDaniele Castagnolo
Daniele Castagnolo

11 May 2020 in ACS Catalysis
Verified
Journal Article
Closed access
FZFei Zhao
Fei Zhao
Domiziana MasciDomiziana Masci
Domiziana Masci
SFSalvatore Ferla
Salvatore Ferla
CVCarmine Varricchio
Carmine Varricchio
ABAndrea Brancale
Andrea Brancale
Daniele CastagnoloDaniele Castagnolo
Daniele Castagnolo

9 November 2023 in Molecules
Verified
Journal Article
Open access
PDF file
Domiziana MasciDomiziana Masci
Domiziana Masci
CNChiara Naro
Chiara Naro
MPMichela Puxeddu
Michela Puxeddu
AUAndrea Urbani
Andrea Urbani
CSClaudio Sette
Claudio Sette
RSRomano Silvestri
Romano Silvestri
Triple-negative breast cancer (TNBC) is one of the most heterogeneous and aggressive breast cancer subtypes with a high risk of death on recurrence. To date, TNBC is very difficult to treat due to the lack of an effective targeted therapy. However, recent advances in the molecular characterization of TNBC are encouraging the development of novel drugs and therapeutic combinations for its therapeutic management. In the present review, we will provide an overview of the currently available standard therapies and new emerging therapeutic strategies against TNBC, highlighting the promises that newly developed small molecules, repositioned drugs, and combination therapies have of improving treatment efficacy against these tumors.

23 July 2024 in Antioxidants
Verified
Journal Article
Open access
PDF file
APAnna Percio
Anna Percio
MCMichela Cicchinelli
Michela Cicchinelli
Domiziana MasciDomiziana Masci
Domiziana Masci
MSMariagrazia Summo
Mariagrazia Summo
AUAndrea Urbani
Andrea Urbani
VGViviana Greco
Viviana Greco
Redox dysregulation, an imbalance between oxidants and antioxidants, is crucial in the pathogenesis of various neurodegenerative diseases. Within this context, the “redoxome” encompasses the network of redox molecules collaborating to maintain cellular redox balance and signaling. Among these, cysteine-sensitive proteins are fundamental for this homeostasis. Due to their reactive thiol groups, cysteine (Cys) residues are particularly susceptible to oxidative post-translational modifications (PTMs) induced by free radicals (reactive oxygen, nitrogen, and sulfur species) which profoundly affect protein functions. Cys-PTMs, forming what is referred to as “cysteinet” in the redox proteome, are essential for redox signaling in both physiological and pathological conditions, including neurodegeneration. Such modifications significantly influence protein misfolding and aggregation, key hallmarks of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and notably, amyotrophic lateral sclerosis (ALS). This review aims to explore the complex landscape of cysteine PTMs in the cellular redox environment, elucidating their impact on neurodegeneration at protein level. By investigating specific cysteine-sensitive proteins and the regulatory networks involved, particular emphasis is placed on the link between redox dysregulation and ALS, highlighting this pathology as a prime example of a neurodegenerative disease wherein such redox dysregulation is a distinct hallmark.